Suppr超能文献

新冠病毒再感染:我们是否夸大了担忧?

Re-infection in COVID-19: Do we exaggerate our worries?

机构信息

Department of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, Batman, Turkey.

Batman Provincial Health Directorate, TR Ministry of Health, Batman, Turkey.

出版信息

Eur J Clin Invest. 2022 Jun;52(6):e13767. doi: 10.1111/eci.13767. Epub 2022 Mar 25.

Abstract

BACKGROUND

Protective long-term immunity following coronavirus disease 2019 (COVID-19) is unclear. The study evaluated the relationship between the vaccination status and risk factors in the re-infection of patients with a diagnosis of COVID-19 who reported to the Public Health Management System in a province in south-eastern Turkey.

METHODS

Patients with positive results for the severe acute respiratory syndrome coronavirus 2 by the real-time reverse transcription polymerase chain reaction (RT-PCR) test in respiratory samples were defined as confirmed cases. Reinfection was diagnosed in cases with COVID-19 real-time RT-PCR positivity, with or without COVID-19-like symptoms, in at least 90 days after the first infection/disease.

RESULTS

A total of 58 811 patients with the diagnosis of COVID-19 from March 11, 2020, to August 31, 2021, were included in the study. Re-infection was detected in 421 (0.7%) of all patients. The mean age of the cases was 38.0±16.0 years, and 51% of them were female. Eight (2.0%) of the cases resulted in death due to re-infection. No hospitalization or mortality was observed in fully vaccinated patients. Additionally, none of the mortal cases had completed the vaccination schedule.

CONCLUSIONS

We are concerned that the re-infection rates and mortality may increase due to new variant strains. Vaccination is the greatest weapon against progression to critical illness in re-infections, even with existing mutations. Therefore, it is important for those without a full vaccination schedule to be vaccinated, even if they have been previously infected.

摘要

背景

新冠肺炎(COVID-19)后保护性的长期免疫尚不清楚。本研究评估了土耳其东南部一省公共卫生管理系统报告的 COVID-19 诊断患者中,疫苗接种状况与再感染风险因素之间的关系。

方法

通过呼吸道样本实时逆转录聚合酶链反应(RT-PCR)检测严重急性呼吸综合征冠状病毒 2 呈阳性的患者被定义为确诊病例。在首次感染/发病至少 90 天后,COVID-19 实时 RT-PCR 阳性,伴有或不伴有 COVID-19 样症状的患者被诊断为再感染。

结果

本研究共纳入 2020 年 3 月 11 日至 2021 年 8 月 31 日期间诊断为 COVID-19 的 58811 例患者。在所有患者中,检测到 421 例(0.7%)再感染。病例的平均年龄为 38.0±16.0 岁,51%为女性。8 例(2.0%)再感染病例死亡。完全接种疫苗的患者未发生住院或死亡。此外,没有死亡病例完成了疫苗接种计划。

结论

我们担心新变异株可能会导致再感染率和死亡率增加。即使存在现有突变,接种疫苗仍是防止再感染进展为重症的最佳手段。因此,对于未完成全疫苗接种计划的人,即使之前已感染过,接种疫苗也很重要。

相似文献

1
Re-infection in COVID-19: Do we exaggerate our worries?新冠病毒再感染:我们是否夸大了担忧?
Eur J Clin Invest. 2022 Jun;52(6):e13767. doi: 10.1111/eci.13767. Epub 2022 Mar 25.
3
SARS-CoV-2 re-infection risk in Austria.奥地利的 SARS-CoV-2 再感染风险。
Eur J Clin Invest. 2021 Apr;51(4):e13520. doi: 10.1111/eci.13520. Epub 2021 Feb 21.

引用本文的文献

3
Safety and efficiency of COVID-19 vaccine in North Africa.北非地区 COVID-19 疫苗的安全性和有效性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2306703. doi: 10.1080/21645515.2024.2306703. Epub 2024 Feb 2.

本文引用的文献

9
Does SARS-CoV-2 re-infection depend on virus variant?新型冠状病毒2型(SARS-CoV-2)的再次感染是否取决于病毒变体?
Clin Microbiol Infect. 2021 Sep;27(9):1374-1375. doi: 10.1016/j.cmi.2021.06.029. Epub 2021 Jun 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验